Loading
A comprehensive, evidence-based comparison of hemodialysis (HD) and peritoneal dialysis (PD) — covering outcomes, lifestyle, cost, and suitability for Indian patients.
Evidence reviewed & updated: 2026-07 — reflects the latest published trials and guidelines.
Both hemodialysis (HD) and peritoneal dialysis (PD) provide comparable survival outcomes in most patient populations. The choice depends on lifestyle, vascular access suitability, patient preference, home support, and local availability. PD offers independence and flexibility; HD offers professionally managed care. In India, PD remains underutilized at ~12-15% of dialysis patients despite guideline recommendations favoring patient-centered modality selection.
Randomized trials comparing HD and PD are limited, but large registry analyses show comparable adjusted mortality. The Dutch NECOSAD study found PD patients had better survival in the first 1-2 years, especially younger non-diabetic patients (Termorshuizen et al., 2003, JASN). USRDS data shows similar overall adjusted survival, with HD favored in older diabetic patients.
Residual kidney function is a key differentiator. PD is consistently associated with slower decline of residual renal function — critical because residual GFR correlates strongly with survival (CANUSA Study Group, 1996; Bargman et al., 2001). Each 1 mL/min higher residual GFR is associated with ~7-8% lower mortality.
Peritonitis is the major PD complication (target: <0.4 episodes/patient-year per ISPD 2022 guidelines), while HD carries vascular access complications (thrombosis, infection). Both modalities have comparable hospitalization rates when treated at experienced centers.
PD is performed at home — CAPD requires 4-5 manual exchanges daily (30 min each), APD uses an automated cycler overnight. Patients maintain work schedules, travel freely (supplies can be delivered), and avoid thrice-weekly hospital visits.
In-center HD requires 3 visits/week, 4 hours each, plus travel time — a significant burden for employed patients and those in rural areas. Home HD offers flexibility but requires 4-8 weeks of training and a partner.
The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) shows that patient-reported quality of life is generally higher on PD, particularly for employment and travel domains.
In India, in-center HD costs approximately ₹12,000-20,000/month (2-3 sessions/week including consumables), with significant out-of-pocket expenses. PD with Baxter/Claris supplies costs ₹15,000-22,000/month initially but offers long-term cost advantages: fewer hospital visits, preserved residual function reducing ESA and phosphate binder needs.
The Indian government's PD-First initiative (Tamil Nadu, 2017-2020) demonstrated that PD is feasible at scale in India, achieving comparable outcomes to HD at lower total cost. The Bhoomi program (New Delhi) provides subsidized PD support for children.
ISN India estimates PD utilization at only 12-15% of dialysis patients versus 25-30% in countries like Australia, New Zealand, and Hong Kong — where 'PD-First' policies are standard. This gap represents both a clinical and cost optimization opportunity.
PD is preferred in: patients with residual kidney function, working professionals, remote/rural residents, patients with cardiovascular instability, and children (PD is standard in pediatric nephrology).
HD is preferred in: patients with prior major abdominal surgery, recurrent peritonitis, inadequate peritoneal clearance, patients without home support, and those with cognitive impairment affecting exchange technique.
Absolute contraindications to PD: surgically uncorrectable abdominal hernia, extensive abdominal adhesions, and documented loss of peritoneal membrane function. Relative contraindications: obesity (BMI >35), severe COPD, and ostomies.
Modality education should start at CKD Stage 4 — at least 6-12 months before dialysis initiation. Facilities offering both modalities retain more patients and capture referrals that would otherwise go to competing centers.
Implementing a PD program requires: trained nursing staff, patient training space, supply logistics, and outcome tracking (peritonitis rates, PD adequacy Kt/V, technique survival). ZuvFlo's home dialysis module supports PD patient monitoring, training documentation, and supply automation.
Data from the National Registry in India shows that centers offering both HD and PD grow their patient base 20-30% faster — patients prefer facilities that present modality choices transparently.
Advertisement
Online hemodiafiltration (HDF) combines diffusive clearance (HD) with convective clearance via ultrafiltration and subst...
Learn moreCAPD uses 4-5 manual exchanges per day (30 min each); APD uses an automated cycler overnight while the patient sleeps. B...
Learn moreHome hemodialysis (short daily 5-6x/week or nocturnal 6x/week) delivers superior outcomes to conventional thrice-weekly ...
Learn moreSGLT2 inhibitors (dapagliflozin, empagliflozin) are the most impactful CKD therapy advance in a decade. DAPA-CKD (NEJM 2...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.